| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NEW BRUNSWICK, N.J., and CAMBRIDGE, Mass—Johnson & Johnson and Millennium Pharmaceuticals have recalled thousands of vials of the cancer drug Velcade (bortezomib) sold in Europe, the United States, Japan and Malaysia after reports of white particles floating in batches of the medicine distributed between January and June of this year.

Velcade, known chemically as bortezomib, is approved to treat multiple myeloma and relapsed mantle cell lymphoma. It is sold in the United States by Millennium, which is a unit of Japanese company Takeda Pharmaceutical Co. and by Janssen-Cilag, a unit of Johnson & Johnson, in Europe and the rest of the world.

As unwanted as the recall might be for Millennium and its parent company, the news is probably less palatable to Johnson & Johnson, which has already had to deal with massive recalls of many over-the-counter consumer health products, including Children's Tylenol and Motrin—a total of some 40 medicines in the past year.

The particles in the Velcade batches have been identified as a polyester-like material that is associated with a component of the manufacturing process that is performed by a contract manufacturer for Millennium. The manufacturing problem linked with the presence of the particles is being corrected, according to Seizo Masuda, a spokesperson for Takeda in Tokyo.

Some 200,000 vials were produced in the affected lots for the United States, and almost that many in Europe, but the vast majority of those vials have already been administered to patients, so Johnson & Johnson expects to recover only 20,000 vials, and Millennium anticipates recapturing roughly half that number. As yet, there have been no confirmed reports of adverse events related to use of the affected vials, and the companies are calling the recall effort a "precautionary measure."
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue